Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals will host an investor call on October 12, 2026 at 8:30 a.m. ET to share topline results from the Phase 3 EXPAND study. The study evaluates LIVMARLI (maralixibat) for cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia.
Key figures
- Drug Name
- LIVMARLI (maralixibat)
- Phase Of Trial
- Phase 3
- Call datetime
- Monday, October 12, 2026 at 8:30 a.m. ET
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.